Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Targeted therapies

Cetuximab plus chemotherapy in patients with advanced NSCLC

Nature Reviews Clinical Oncology volume 6, pages 499–500 (2009)Cite this article

Targeting EGFR in patients with non-small-cell lung cancer (NSCLC) in addition to chemotherapy might provide survival benefits in patients with EGFR-positive tumors. Indeed, results from the FLEX trial demonstrate that cetuximab in combination with platinum-based chemotherapy is a new treatment strategy for patients with advanced NSCLC.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Schematic of EGFR signal transduction pathway.

References

  1. Pirker, R. et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373, 1525–1531 (2009).

    Article  CAS  Google Scholar 

  2. Rosell, R. et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann. Oncol. 19, 362–369 (2008).

    Article  CAS  Google Scholar 

  3. Lynch, T. J. et al. Overall survival (OS) results from the phase III trial BMS 099: cetuximab+taxane/carboplatin as 1st-line treatment for advanced NSCLC. J. Thorac. Oncol. 3, S305 (2008).

    Article  Google Scholar 

  4. Herbst, R. S. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol. 22, 785–794 (2004).

    Article  CAS  Google Scholar 

  5. Gatzemeier, U. et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 25, 1545–1552 (2007).

    Article  CAS  Google Scholar 

  6. Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408–1417 (2009).

    Article  CAS  Google Scholar 

  7. Tsao, M. S. et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133–144 (2005).

    Article  CAS  Google Scholar 

  8. Eberhard, A. et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900–5909 (2005).

    Article  CAS  Google Scholar 

  9. Khambata-Ford, S. et al. K-RAS mutations and EGFR-related markers as potential predictors of cetuximab benefit in 1st line advanced NSCLC: results from the BMS-099 study. J. Thorac. Oncol. 3, S304 (2008).

    Google Scholar 

  10. Gatzemeter, V. et al. FLEX: cetuximab in combination with platinum-based chemotherapy improves survival versus CT alone for NSCLC. J. Thorac. Oncol. 3, S265 (2008).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Al Amal Cancer Center, Doha, Qatar

    Kakil Ibrahim Rasul

  2. SIDRA Medical and Research Center, Doha, Qatar

    David J. Kerr

Authors
  1. Kakil Ibrahim Rasul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. Kerr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David J. Kerr.

Ethics declarations

Competing interests

Dr. David Kerr is on the Speakers bureau at Merk KGA. Dr. Rasul declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rasul, K., Kerr, D. Cetuximab plus chemotherapy in patients with advanced NSCLC. Nat Rev Clin Oncol 6, 499–500 (2009). https://doi.org/10.1038/nrclinonc.2009.108

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.108

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing